The purpose of this research registry is to evaluate the effectiveness of a technology; called Fractional Flow Reserve (FFR-CT); a computer assessment; that could clarify the results of the coronary computed tomography angiogram (CCTA); in patients with coronary artery disease. The results from the FFR-CT analysis may help; guide treatment recommendations by providing additional information; about the patient’s CCTA scan results.
So, the ADVANCE Registry; sponsored by HeartFlow (the company that developed FFR-CT technology); does not require any additional healthcare visits or scans. CCTA scans are sent to HeartFlow for FFR-CT measurement; and participants will be contacted for follow-up questionnaires; regarding heart-related health care five times over three years.

Non-invasive technology to evaluate heart pain

So, one-year follow-up results show that a newer; non-invasive technology to evaluate heart pain provided a reliable way; to identify which patients had dangerous artery blockages; according to a study co-led by the Duke Clinical Research Institute. However, the findings, reported at the American College of Cardiology meeting, suggest that fractional flow reserve CT (FFR-CT) scans are effective in helping doctors determine which patients need more aggressive treatments.

“Our study shows that in clinical practice, when new technology provides a negative result regarding the chance for a physiologically significant stenosis, the patient and physician should be reassured that the chances of major adverse cardiac events are low,” said lead author Manesh Patel, M.D., chief of the Division of Cardiology at Duke University School of Medicine.

Low risk for a major heart event

Patel and colleagues analyzed data from more than 5,000 patients who underwent FFR-CT scans for clinically suspected coronary artery disease. In patients with moderate-to-severe coronary artery disease, a negative FFR-CT; associated with a low, one-year risk of a major cardiac event such as heart attack or death compared to patients with a positive FFR-CT.

Specifically, the researchers found that among those with an FFR-CT reading above 0.80, suggesting blood flow; not dangerously restricted, the cardiovascular death and heart attack risks were significantly lower; and revascularization was significantly lower (5.8 percent vs. 38.4 percent) and was unlikely after 90 days. “This research, with one-year follow-up, suggests that an FFR-CT test can be trusted when used as it was in this real-world observational registry,” Patel said. “And while we don’t have perfect warranties in medicine, a negative FFR-CT result was seen to have low risk for a major heart event in the following year.”